New Filings At The EMA
Executive Summary
New medicines under evaluation at the European Medicines Agency.
You may also be interested in...
Alexion’s Soliris Successor Among New Drugs Under EMA Review
Alexion Pharmaceuticals’ successor to its blockbuster Soliris is among the new investigational drugs being reviewed for EU marketing approval.
Celgene, Agios Drug Enasidenib Among New Filings At EMA
Enasidenib, which last year became the first US-approved treatment for relapsed or refractory acute myeloid leukemia with an IDH2 mutation, is among a new crop of products being reviewed for marketing approval in the EU.
Australia Becomes First Country To Regulate Psilocybin & MDMA As Medicines
The Therapeutic Goods Administration said its decision to down-schedule two psychedelic substances to controlled drug status followed extensive public consultation, a report from an independent expert panel, and advice from the Advisory Committee on Medicines Scheduling.